Welcome!

News Feed Item

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

LONDON, April 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/non_small_cell_lung_cancer_global_clinical_trials_review.html

Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014" provides data on the Non-Small Cell Lung Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Small Cell Lung Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Small Cell Lung Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Introduction 6
Non-Small Cell Lung Cancer 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Non-Small Cell Lung Cancer 25
Subjects Recruited Over a Period of Time 57
Clinical Trials by Sponsor Type 58
Prominent Sponsors 59
Top Companies Participating in Non-Small Cell Lung Cancer Therapeutics Clinical Trials 60
Prominent Drugs 62

Latest Clinical Trials News on Non-Small Cell Lung Cancer 63
Mar 02, 2014: Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer 63
Feb 19, 2014: Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival 63
Feb 17, 2014: Afatinib: added benefit depends on mutation status 64
Jan 27, 2014: Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer 65
Jan 16, 2014: ArQule Provides Updates on Clinical Trials in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer with Tivantinib 66
Clinical Trial Profiles 68
Clinical Trial Overview of Top Companies 68
F. Hoffmann-La Roche Ltd. 68
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 68
Eli Lilly and Company 84
Clinical Trial Overview of Eli Lilly and Company 84
AstraZeneca PLC 98
Clinical Trial Overview of AstraZeneca PLC 98
Pfizer Inc. 109
Clinical Trial Overview of Pfizer Inc. 109
Bristol-Myers Squibb Company 117

Clinical Trial Overview of Bristol-Myers Squibb Company 117
Sanofi 123
Clinical Trial Overview of Sanofi 123
Novartis AG 128
Clinical Trial Overview of Novartis AG 128
Merck & Co., Inc. 133
Clinical Trial Overview of Merck & Co., Inc. 133
GlaxoSmithKline plc 137
Clinical Trial Overview of GlaxoSmithKline plc 137
C. H. Boehringer Sohn AG & Co. KG 141
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 141
Clinical Trial Overview of Top Institutes / Government 145
National Cancer Institute 145
Clinical Trial Overview of National Cancer Institute 145
The University of Texas M. D. Anderson Cancer Center 168
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 168
Memorial Sloan Kettering Cancer Center 172
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 172
West Japan Oncology Group 176
Clinical Trial Overview of West Japan Oncology Group 176
European Organization for Research and Treatment of Cancer 179
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 179
Radiation Therapy Oncology Group 182
Clinical Trial Overview of Radiation Therapy Oncology Group 182
Sun Yat-sen University 184
Clinical Trial Overview of Sun Yat-sen University 184

Eastern Cooperative Oncology Group 186
Clinical Trial Overview of Eastern Cooperative Oncology Group 186
Sarah Cannon Research Institute 188
Clinical Trial Overview of Sarah Cannon Research Institute 188
Barbara Ann Karmanos Cancer Institute 190
Clinical Trial Overview of Barbara Ann Karmanos Cancer Institute 190
Five Key Clinical Profiles 192
Appendix 292
Abbreviations 292
Definitions 292
Research Methodology 293
Secondary Research 293
About GlobalData 294
Contact Us 294
Disclaimer 294
Source 295

List of Tables

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region, 2014* 7
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase, 2014* 21

Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Non-Small Cell Lung Cancer Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Non-Small Cell Lung Cancer Therapeutics, Global, Withdrawn Clinical Trials, 2014* 28
Non-Small Cell Lung Cancer Therapeutics, Global, Terminated Clinical Trials, 2014* 33
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 57
Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 58
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 59
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 61
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 62
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 68
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 84
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 98

Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 109
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 117
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 123
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 128
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 133
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 137
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 141
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 145
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 168
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 172

Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by West Japan Oncology Group, 2014* 176
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 179
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Radiation Therapy Oncology Group, 2014* 182
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sun Yat-sen University, 2014* 184
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Eastern Cooperative Oncology Group, 2014* 186
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sarah Cannon Research Institute, 2014* 188
Non-Small Cell Lung Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Barbara Ann Karmanos Cancer Institute, 2014* 190

List of Figures
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Non-Small Cell Lung Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17

Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Non-Small Cell Lung Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Non-Small Cell Lung Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 57
Non-Small Cell Lung Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 58
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 59
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 60
Non-Small Cell Lung Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 62
GlobalData Methodology 293

Read the full report:
Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/non_small_cell_lung_cancer_global_clinical_trials_review.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
@DevOpsSummit at Cloud Expo taking place Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center, Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is ...
After more than five years of DevOps, definitions are evolving, boundaries are expanding, ‘unicorns’ are no longer rare, enterprises are on board, and pundits are moving on. Can we now look at an evolution of DevOps? Should we? Is the foundation of DevOps ‘done’, or is there still too much left to do? What is mature, and what is still missing? What does the next 5 years of DevOps look like? In this Power Panel at DevOps Summit, moderated by DevOps Summit Conference Chair Andi Mann, panelists loo...
Cloud applications are seeing a deluge of requests to support the exploding advanced analytics market. “Open analytics” is the emerging strategy to deliver that data through an open data access layer, in the cloud, to be directly consumed by external analytics tools and popular programming languages. An increasing number of data engineers and data scientists use a variety of platforms and advanced analytics languages such as SAS, R, Python and Java, as well as frameworks such as Hadoop and Spark...
"MobiDev is a Ukraine-based software development company. We do mobile development, and we're specialists in that. But we do full stack software development for entrepreneurs, for emerging companies, and for enterprise ventures," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
A look across the tech landscape at the disruptive technologies that are increasing in prominence and speculate as to which will be most impactful for communications – namely, AI and Cloud Computing. In his session at 20th Cloud Expo, Curtis Peterson, VP of Operations at RingCentral, highlighted the current challenges of these transformative technologies and shared strategies for preparing your organization for these changes. This “view from the top” outlined the latest trends and developments i...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, paneli...
The current age of digital transformation means that IT organizations must adapt their toolset to cover all digital experiences, beyond just the end users’. Today’s businesses can no longer focus solely on the digital interactions they manage with employees or customers; they must now contend with non-traditional factors. Whether it's the power of brand to make or break a company, the need to monitor across all locations 24/7, or the ability to proactively resolve issues, companies must adapt to...
SYS-CON Events announced today that TMC has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo and Big Data at Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Global buyers rely on TMC’s content-driven marketplaces to make purchase decisions and navigate markets. Learn how we can help you reach your marketing goals.
Managing mission-critical SAP systems and landscapes has never been easy. Add public cloud with its myriad of powerful cloud native services and this may not change any time soon. Public cloud offers exciting new possibilities for enterprise workloads. But to make use of these possibilities and capabilities, IT teams need to re-think everything they have done before. Otherwise, they will just end up using public cloud as a hosting platform for their workloads, aka known as “lift and shift.”
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing bes...
SYS-CON Events announced today that TechTarget has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TechTarget storage websites are the best online information resource for news, tips and expert advice for the storage, backup and disaster recovery markets.
SYS-CON Events announced today that Telecom Reseller has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
SYS-CON Events announced today that Ayehu will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on October 31 - November 2, 2017 at the Santa Clara Convention Center in Santa Clara California. Ayehu provides IT Process Automation & Orchestration solutions for IT and Security professionals to identify and resolve critical incidents and enable rapid containment, eradication, and recovery from cyber security breaches. Ayehu provides customers greater control over IT infras...